Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease

Hypertension

Volumn 65, Issue 1, 2015, Pages 108-114

  Verdecchia, Paolo ^a   Reboldi, Gianpaolo ^b   Angeli, Fabio ^b   Trimarco, Bruno ^c   Mancia, Giuseppe ^d   Pogue, Janice ^e   Gao, Peggy ^f   Peter, Sleight ^g   Teo, Koon ^a   Yusuf, Salim ^b  

^a Hospital of Assisi   (Italy)

^b Department of Medicine ^*  (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f HAMILTON HEALTH SCIENCES   (Canada)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Blood Pressure; Coronary Artery Disease; Myocardial Infarction; Prognosis; Stroke

Indexed keywords

RAMIPRIL; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TIME; BLOOD PRESSURE; COMPLICATION; DIASTOLE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; STROKE; SYSTOLE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYOCARDIAL INFARCTION; RAMIPRIL; STROKE; SYSTOLE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84919457846     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04310     Document Type: Article

References (39)

1. Anderson TW. Re-examination of some of the Framingham blood-pressure data. Lancet. 1978;2:1139-1141
2. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1:861-865
3. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581-584
4. Cruickshank J. The J-curve in hypertension. Curr Cardiol Rep. 2003;5:441-452
5. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54:1827-1834
6. Williams B. Hypertension and the J-curve. J Am Coll Cardiol. 2009;54:1835-1836
7. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J. 2010;31:2837-2840
8. Sundstrm J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegrd J, Nilsson PM, Johansson G. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients. J Hypertens. 2013;31:1603-1610
9. Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Li W, Johnson J, Heymsfield SB, Cefalu WT, Ryan DH, Hu G. Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care. 2013;36:3287-3296
10. Nilsson PM. The J-shaped curve in secondary prevention: shall clinical practice change? Hypertension. 2012;59:8-9
11. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357
12. Reboldi G, Angeli F, de Simone G, Staessen JA, Verdecchia P; Cardio-Sis Investigators. Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension. 2014;63:475-482
13. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Reboldi G. Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement. Hypertension. 2014;63:37-40
14. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559
15. Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML. The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Circulation. 1988;77:1108-1115
16. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in highrisk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61
17. El Assad M, Topouchian J, Le Dudal K, Labaki G, Asmar R. Validation of the OMRON MR-I blood pressure device according to the international validation protocol. J Hypertens. 2003;21(suppl. 4):S23
18. Verdecchia P, Angeli F, Reboldi G, Carluccio E, Benemio G, Gattobigio R, Borgioni C, Bentivoglio M, Porcellati C, Ambrosio G. Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens. 2003;16:646-652
19. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-2483
20. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000
21. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551-561
22. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed. 1997;54:201-208
23. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001
24. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884-893
25. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Bhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:1360-1369
26. Cruickshank JM. Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther. 2000;14:373-379
27. Burnham KP, Anderson DR. Model Selection and Inference: A Practical Information-Theoretic Approach. New York: Springer; 1998
28. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489-495
29. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC; Treating to New Targets Steering Committee and Investigators. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897-2908
30. Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM; PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137-2144
31. Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, Leonetti G, Tuomilehto J, Yodfat Y. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167:1884-1891
32. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253-1269
33. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828
34. Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI, Fang JC. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials. Stroke. 2012;43:432-440
35. Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833-838
36. Sleight P. Blood pressure levels for treatment of uncomplicated diabetes in primary care. J Hypertens. 2013;31:1527-1528
37. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520
38. Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499-503
39. Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, Kissela BM, Kittner SJ, Lichtman JH, Lisabeth LD, Schwamm LH, Smith EE, Towfighi A; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Council on Functional Genomics and Translational Biology. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315-353